公开(公告)号：US20230139684A1

公开(公告)日：2023-05-04

申请号：US17778369

申请日：2020-11-23

申请人： Brown University

发明人： John M. SEDIVY ,  Gerwald JOGL ,  Alexandra D'ORDINE

IPC分类号： A61K31/4741 ,  A61K31/198 ,  A61K31/366 ,  A61K31/145 ,  A61K31/17 ,  A61K31/4192 ,  A61K31/445 ,  A61K31/166 ,  A61K31/167 ,  A61K31/64 ,  A61K31/4035 ,  A61K31/505 ,  A61K31/423 ,  A61K31/381 ,  A61K31/53 ,  A61K31/635

摘要： Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one LINE 1 (L-1) endonuclease inhibitor.

公开(公告)号：US20230131476A1

公开(公告)日：2023-04-27

申请号：US17907451

申请日：2021-04-01

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： CLAUDIA ROESSLE ,  DENIS BREUILLE ,  EUGENIA MIGLIAVACCA ,  JEROME FEIGE

IPC分类号： A61K31/4172 ,  A61K31/198 ,  A61K31/405 ,  A61K31/675 ,  A61P21/00

摘要： A composition contains one or more aromatic amino acids and optionally vitamin B6. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be in a form of a powder, a powdered stick, a capsule or a solution. The composition can be administered to an individual in need thereof orally or intravenously for preventing and/or treating sarcopenia, a loss of and/or improving skeletal muscle mass, lean muscle mass, skeletal muscle strength and/or skeletal muscle function.

公开(公告)号：US20230129413A1

公开(公告)日：2023-04-27

申请号：US17817191

申请日：2022-08-03

申请人： AbbVie Inc.

发明人： Alexandru DEAC ,  Ye HUANG ,  John M. LIPARI ,  Alexander RUGGLES ,  Thin Yu TUN

IPC分类号： A61K31/198 ,  A61K47/32 ,  A61K47/10 ,  A61K47/38 ,  A61K9/10 ,  A61K9/00 ,  A61K31/195

摘要： The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

公开(公告)号：US20230126763A1

公开(公告)日：2023-04-27

申请号：US17979670

申请日：2022-11-02

申请人： Io Therapeutics, Inc.

发明人： Roshantha A. Chandraratna ,  Martin E. Sanders

IPC分类号： A61K31/216 ,  A61P35/00 ,  A61P25/16 ,  A61P25/28 ,  A61P21/00 ,  A61K45/06 ,  A61P37/02 ,  A61K31/198

摘要： The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.

公开(公告)号：US11633452B2

公开(公告)日：2023-04-25

申请号：US17080930

申请日：2020-10-27

申请人： The Procter & Gamble Company

发明人： Travis Kyle Hodgdon ,  Leo Timothy Laughlin, II ,  Samantha Chen-Yee Wang ,  Robert Lloyd Binder

IPC分类号： A61K38/08 ,  A61P15/02 ,  A61K9/107 ,  A61K31/198 ,  A61K31/355 ,  A61K38/06 ,  A61K47/44 ,  A61K9/16 ,  A61K31/047 ,  A61K31/407 ,  A61K36/22 ,  A61K36/48 ,  A61K36/49 ,  A61K36/54 ,  A61K36/899

摘要： A method of treating vaginal dryness by administering a vaginal care composition, which includes an effective amount of a vaginal care agent, to vaginal tissue of a user experiencing vaginal dryness. The vaginal care agent may be selected to specifically treat symptoms of vaginal dryness exhibited by the introitus and/or labia, based on the transcriptomic data of skin cells obtained therefrom. In some instances, the vaginal care composition may be applied to introitus and/or labia with a suitable implement configured for such use.

公开(公告)号：US11633376B2

公开(公告)日：2023-04-25

申请号：US17120228

申请日：2020-12-13

申请人： THE WILLIAM M YARBROUGH FOUNDATION

发明人： Michael E. Silver

IPC分类号： A61K31/26 ,  A61K31/16 ,  A61K31/195 ,  A61K31/198 ,  A61K9/00 ,  A61K9/06

摘要： A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

公开(公告)号：US11628170B2

公开(公告)日：2023-04-18

申请号：US16503128

申请日：2019-07-03

申请人： Sinopia Biosciences, Inc.

发明人： Aarash Bordbar

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K45/06 ,  A61K31/53 ,  A61K31/5377 ,  A61P25/14 ,  A61P25/18 ,  A61K31/198

摘要： Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230111960A1

公开(公告)日：2023-04-13

申请号：US18045264

申请日：2022-10-10

申请人： Iowa State University Research Foundation, Inc.

发明人： Mark Lyte

IPC分类号： A61K35/744 ,  A61K31/198 ,  A61K36/48 ,  A61K36/81 ,  A61P37/04

摘要： The present disclosure is directed to dopamine producing probiotics to increase immune responses to vaccination and to provide increased immune protection. The present disclosure is further directed to dopamine producing synbiotic compositions, formulations, plants, and synthetic compounds and their use for targeted clinical and veterinary applications, for example, in promoting health and well-being and enhancing vaccine efficacy. The present disclosure also provides an approach for optimization of synbiotic delivery of a probiotic or other dopamine producing product with a dopamine precursor to beneficially aid in the use of such products for a variety of conditions and diseases, and particularly in the field of vaccines, whether prophylactic or therapeutic.

公开(公告)号：US20230110614A1

公开(公告)日：2023-04-13

申请号：US17802711

申请日：2021-03-19

申请人： Atossa Therapeutics, Inc.

发明人： Steven C. QUAY

IPC分类号： A61K31/727 ,  A61K31/198 ,  A61K9/00 ,  A61K47/18 ,  A61K45/06

摘要： Disclosed herein are compositions and methods for treatment or prevention of a respiratory viral infection. A composition of the present disclosure comprises one or more of heparin, or N-acetylcysteine. A composition for treatment or prevention of a respiratory viral infection may be administered by inhalation in intervals. Administration of a composition may treat or prevent a viral infection.

公开(公告)号：US11617771B2

公开(公告)日：2023-04-04

申请号：US16470040

申请日：2017-12-15

申请人： The Regents of the University of California

发明人： Anahid Jewett

IPC分类号： A61K35/744 ,  A61P35/00 ,  A61K33/243 ,  A61K31/198 ,  A61K31/337 ,  A61K35/17 ,  A61K35/32 ,  A61K35/745 ,  A61K35/747 ,  A61K45/06 ,  C12N5/0783 ,  C12N5/077 ,  C12N5/09 ,  A61K35/00

摘要： The present application relates to probiotic compositions, e.g., comprising at least one bacterial strain selected from: Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, KE99, and Lactobacillus bulgaricus, optionally wherein the at least one bacterial strain is either alive or sonicated.